NewsRoom Articles - BioMedWire (BMW)

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

TuesdayMar 24, 2026 10:00 am

Misinformation Could Thwart the Potential of Cancer Vaccines

For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is being registered in developing mRNA vaccines against cancer, but this progress has come up against a wall of misinformation that could thwart the prospects of this promising intervention. Most people first heard about mRNA vaccines during the Covid-19 pandemic when these vaccines were widely used to bring the pandemic under control. However, misinformation soon spread that these vaccines were not only accelerating cancer rates but also causing cancer to be “turbo-charged.” Social media was awash with stories of “turbo cancer” starting in 2021 and mainstream media caught…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

TuesdayMar 24, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL. Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning…

FridayMar 20, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs. The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease. The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide. Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet…

FridayMar 20, 2026 10:00 am

Oncolytic Virus Therapy is Set to Transform Cancer Care

Enormous resources are being channeled into studying different ways to support the immune system in its fight against cancer. One emerging approach is the use of oncolytic viruses. This approach seeks to leverage viruses to destroy cancer by attacking and killing its cells. The approach stems from the discovery that a number of cancers are linked to viral infections, such as HPV, which has been linked to the development of head and neck cancer, as well as cervical cancer. Liver cancer has also been linked to the hepatitis B virus. A number of vaccines have been developed to prevent some of these cancers by preventing infection by these viruses. Scientists are now looking to go a step further by…

FridayMar 20, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments. Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells. Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is…

ThursdayMar 19, 2026 10:00 am

Study Finds That Marijuana Legalization Lowers Crime Rates

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers, including doctors, nurse practitioners and nurses have flocked to the Canadian province in search of employment and have secured jobs. Speaking at BC Children’s Hospital on Tuesday, the premier pointed out that the progressive social values, lifestyle and public healthcare system have been instrumental in attracting U.S.-trained medical workers to B.C. He added that the province respected science while making public health policies, has a high standard of living and respects reproductive rights. These, he said, have made the province an attractive place for healthcare workers from America. He highlighted that the…

WednesdayMar 18, 2026 11:15 am

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services. Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside…

WednesdayMar 18, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications. The broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure. Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

Misinformation Could Thwart the Potential of Cancer Vaccines

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Oncolytic Virus Therapy is Set to Transform Cancer Care

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Study Finds That Marijuana Legalization Lowers Crime Rates

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search